1. Home
  2. VRTX vs DASH Comparison

VRTX vs DASH Comparison

Compare VRTX & DASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • DASH
  • Stock Information
  • Founded
  • VRTX 1989
  • DASH 2013
  • Country
  • VRTX United States
  • DASH United States
  • Employees
  • VRTX N/A
  • DASH N/A
  • Industry
  • VRTX EDP Services
  • DASH Industrial Machinery/Components
  • Sector
  • VRTX Technology
  • DASH Industrials
  • Exchange
  • VRTX Nasdaq
  • DASH Nasdaq
  • Market Cap
  • VRTX 115.6B
  • DASH 109.4B
  • IPO Year
  • VRTX 1991
  • DASH 2020
  • Fundamental
  • Price
  • VRTX $398.10
  • DASH $246.27
  • Analyst Decision
  • VRTX Buy
  • DASH Buy
  • Analyst Count
  • VRTX 24
  • DASH 32
  • Target Price
  • VRTX $496.76
  • DASH $266.16
  • AVG Volume (30 Days)
  • VRTX 2.5M
  • DASH 3.9M
  • Earning Date
  • VRTX 08-04-2025
  • DASH 08-06-2025
  • Dividend Yield
  • VRTX N/A
  • DASH N/A
  • EPS Growth
  • VRTX N/A
  • DASH N/A
  • EPS
  • VRTX 14.07
  • DASH 1.76
  • Revenue
  • VRTX $11,418,800,000.00
  • DASH $11,895,000,000.00
  • Revenue This Year
  • VRTX $10.40
  • DASH $22.29
  • Revenue Next Year
  • VRTX $10.63
  • DASH $19.78
  • P/E Ratio
  • VRTX $28.24
  • DASH $139.62
  • Revenue Growth
  • VRTX 10.46
  • DASH 23.78
  • 52 Week Low
  • VRTX $362.50
  • DASH $122.32
  • 52 Week High
  • VRTX $519.88
  • DASH $278.15
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 43.02
  • DASH 47.55
  • Support Level
  • VRTX $388.93
  • DASH $233.11
  • Resistance Level
  • VRTX $400.94
  • DASH $254.16
  • Average True Range (ATR)
  • VRTX 12.48
  • DASH 8.52
  • MACD
  • VRTX 1.47
  • DASH -2.26
  • Stochastic Oscillator
  • VRTX 72.97
  • DASH 26.35

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About DASH DoorDash Inc.

Founded in 2013 and headquartered in San Francisco, DoorDash is an online delivery demand aggregator. Consumers can use its app to order food items on-demand for delivery or in-store from merchants. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe and Asia. DoorDash creates a marketplace for merchants to establish a presence online, market their offerings, and meet demand through delivery. The firm provides similar service to nonrestaurant businesses, such as grocery, retail, and pet supplies. Dash is also rolling out nascent technology like drone delivery in an effort to continually innovate and provide the best possible service to supply-side and demand-side contingents of its marketplace.

Share on Social Networks: